- Home
- CAPR vs TYRA Comparison
CAPR vs TYRA Comparison
Compare CAPR & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- TYRA
- Stock Information
- Founded
- CAPR 2005
- TYRA 2018
- Country
- CAPR United States
- TYRA United States
- Employees
- CAPR N/A
- TYRA N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- TYRA Biotechnology: Pharmaceutical Preparations
- Sector
- CAPR Health Care
- TYRA Health Care
- Exchange
- CAPR Nasdaq
- TYRA Nasdaq
- Market Cap
- CAPR 867.6M
- TYRA 812.7M
- IPO Year
- CAPR N/A
- TYRA 2021
- Fundamental
- Price
- CAPR $13.07
- TYRA $14.00
- Analyst Decision
- CAPR Strong Buy
- TYRA Strong Buy
- Analyst Count
- CAPR 7
- TYRA 5
- Target Price
- CAPR $39.29
- TYRA $31.00
- AVG Volume (30 Days)
- CAPR 1.8M
- TYRA 219.5K
- Earning Date
- CAPR 11-13-2024
- TYRA 11-07-2024
- Dividend Yield
- CAPR N/A
- TYRA N/A
- EPS Growth
- CAPR N/A
- TYRA N/A
- EPS
- CAPR N/A
- TYRA N/A
- Revenue
- CAPR $23,228,045.00
- TYRA N/A
- Revenue This Year
- CAPR N/A
- TYRA N/A
- Revenue Next Year
- CAPR $74.85
- TYRA N/A
- P/E Ratio
- CAPR N/A
- TYRA N/A
- Revenue Growth
- CAPR 65.33
- TYRA N/A
- 52 Week Low
- CAPR $3.52
- TYRA $11.24
- 52 Week High
- CAPR $23.40
- TYRA $29.60
- Technical
- Relative Strength Index (RSI)
- CAPR 37.42
- TYRA 32.68
- Support Level
- CAPR $12.25
- TYRA $14.65
- Resistance Level
- CAPR $20.75
- TYRA $15.55
- Average True Range (ATR)
- CAPR 1.62
- TYRA 0.72
- MACD
- CAPR -0.24
- TYRA 0.02
- Stochastic Oscillator
- CAPR 9.65
- TYRA 3.12
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).